 News
2008
 PolyTherics and Alligator Bioscience announces strategic collaboration for optimisation of next generation biopharmaceuticals
 Secretary of State John Denham visits PolyTherics
Novel Approach to Drug Insolubility strengthens PolyTherics patent estate
PolyTherics expands Collaboration with Biocompatibles
PolyTherics-Celtic Pharma Collaboration Agreement to explore technologies for improved drug performance
New Consortium announces Significant Grant Funding of Anaemia product programme
2007
Innovative Drug Production Project secures funding from Technology Strategy Board
Imperial Innovations Annual Report - PolyTherics Limited
PolyTherics highlighted by UK Trade & Investment
Antony Godwin from PolyTherics ties the knot
PolyTherics and BioVectra dcl sign Manufacturing and Representation Deal
Innovative Biopharmaceutical Company, PolyTherics, raises over £2 million
TheraPEG ™ technology ideal for drugs for developing countries
2006
 TheraPEG ™ technology wins Research Breakthrough Award
NHS at Hammersmith Hospital applauds new PEGylated IFN
PolyTherics nominated Regional Finalist in UK Biotechnology Entrepreneur Awards 2006
PolyTherics PEGylation technology published in Nature
Debbie Allen and Geeta Gupta joins PolyTherics
2005
PolyTherics and Shantha sign biotech deal
BangaloreBio begins
British High Commissioner addresses Indian biotech companies
|
|
Previous | Next
"BangaloreBio kicks off with three deals"
Three major biotech partnership deals were struck on the opening of day of annual biotechnology show -- BangaloreBio 2005.
Shanta Biotechnics is collaborating with PolyTheric of UK.
Edutech a Bangalore based knowledge solutions company is tying up with Zenosis, another UK-based technology company. Randox, a UK-based diagnostic kit maker, is setting up a manufacturing base outside Bangalore which will be the first one outside of its home country.
Shanta Biotech's pact with PolyTherics, a University of London biotech spin-off, involves a technology transfer agreement which will enable Shanta Biotech to licence PolyTherics's novel pegylation technology to make an afforabable PEG-interferon product for the treatment of Hepatitis C.
"The two companies are to collaborate in an accelerated drug development programme in order to commercialise a cost affordable treatment for patients with Hepatitis C," said Sir Michael Arthur, British High Commissioner in India.
"This agreement is a shining example of how exciting innovations in our best universities can be rapidly turned into new and useful global healthcare products," he added.
The pact between Zenosis and Edutech deal will enable Indian life science companies to get their products to the global markets faster by helping them with regulatory compliance.
The deal will also enable Indian bio-pharma companies to meet requirements of regulatory compliance on-line.
According to Simon Burgess, CEO of Zenosis, the company is entering the Indian market with specific modules addressed for local requirements as well.
Randox, a diagnostic kit maker, is investing substantially to set up clinical diagnostics plant in Bangalore.
The company is known to have been the first to develop diagnostics and protein biochips. The company took the decision based on the availability of scientific skills in Bangalore and the ample supply of biochemistry graduates.
Commenting on this increasing trend among global biotechnology companies in tapping Bangalores resources, Kiran Mazumdar Shaw, chairperson, Karnataka task force for Biotech said: "Almost all big pharma and a number of biotech companies are outsouring research and development services form a large number of research services companies based in Bangalore. BangaloreBio 2005 will give a further fillip to this effort. The fact that three major deals have been signed on the first day itself of this event indicates the potential it holds."
BangaloreBio, which was started five years ago, has witnessed some of the prominent and successful bio-partnering deals such as Biocon tying up with Vacinex, CIMAB Cuba, Nobex and Genencor.
In addition to this, Strand Genomics entered into a pact with Medibic of Japan while Avestagen tied up with Genetic ID and Biomerieux.
---
Article by Anil Urs, Business Standard
23 April 2005
[Original article]
This article has been reproduced from the media. It does not necesssarily represent the views or position of PolyTherics.
Previous | Next
|
Privacy Policy | Terms of Use | Browsing
